Connect with us

Business

National Energy Services earnings beat by $0.09, revenue topped estimates

Published

on

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Venture Global faces earnings test after strong Q2 exports

Published

on


Venture Global faces earnings test after strong Q2 exports

Continue Reading

Business

Jeff Bezos & Liverpool: Consortium including American advances talks

Published

on

Amazon founder Jeff Bezos and a picture of a corner flag at Liverpool

A consortium including billionaire Amazon founder Jeff Bezos has advanced its talks to buy about a 30% stake in Liverpool, BBC Sport has been told.

The group is led by British-Indian millionaire businessman Amit Bhatia and also includes Facebook co-founder Eduardo Saverin.

Owners Fenway Sports Group (FSG) confirmed last month that the group had “expressed interest in making a strategic minority investment in Liverpool Football Club”.

Bhatia is the son-in-law of Indian billionaire businessman Lakshmi Mittal and had been a director and co-owner of Queens Park Rangers for 18 years before relinquishing his stake in the club last month.

Advertisement

American businessman Bezos, founder of e-commerce giant Amazon, is the fourth-richest person in the world.

According to Forbes, the 62-year-old has an estimated net worth of $256bn (£192bn).

FSG, who bought Liverpool in a £300m deal in 2010, previously sold a minority stake in the Anfield side to global sports investment firm Dynasty Equity.

Advertisement
Continue Reading

Business

Perion Q2 2026 slides show growth engines accelerating amid transition

Published

on


Perion Q2 2026 slides show growth engines accelerating amid transition

Continue Reading

Business

Materials Processing Institute applies for Company Voluntary Arrangement amid financial challenges

Published

on

Business Live

A restructuring at the research organisation has brought redundancies

Materials Processing Institute(Image: Katie Lunn/Evening Gazette)

A key industrial research facility on Teesside has encountered financial difficulties and applied for an insolvency measure.

The Materials Processing Institute, based in Middlesbrough, is a centre of innovation in the country’s manufacturing sector, where researchers carry out pioneering work in areas such as advanced materials, industrial decarbonisation and digital technologies. It runs a range of facilities including laboratories, a metal alloys making site and offices used by a number of small and medium-sized companies.

Court filings show the not-for-profit organisation – which until recently had employed about 70 people and has roots extending back about eight decades – has applied to make a Company Voluntary Arrangement, a mechanism that insolvent companies can use to pay creditors over a specified time.

The move follows extensive investment in MPI over recent years, including millions of pounds of public funding to tackle productivity, sustainability and competitiveness-driving innovations. Most recently, MPI installed a new, seven-tonne electric arc furnace at its Green Steel Centre on Eston Road, creating a one-of-a-kind facility in the UK.

Advertisement

The equipment was supported by £2.9m grant funding from Innovate UK, part of national funding agency, UK Research and Innovation. In recent years similar sums have been awarded to the institute.

Total capital invested in new research equipment and facilities over the last four years is more than £10m. New facilities also include hydrometallurgy to look at the recycling of electric vehicle batteries and a pilot scale hydrogen gas network for investigations into fuel switching, hydrogen reduction processes and heating.

News of the CVA follows 2025 accounts for loss-making MPI, published in recent weeks, which includes details of problems encountered while trying to diversify the organisation away from a reliance on grant funding.

The company ran into what it called significant cashflow challenges that have prompted a full restructuring of the business – including a significant number of redundancies. Directors talked of the need to financially restructure MPI’s balance sheet, a process which is now being carried out via the CVA.

Advertisement

Within the most recent accounts, MPI said: “The company has experienced a challenging trading period during the year, resulting in losses and pressure on short-term cash flows. In response, management has initiated a restructuring programme aimed at reducing the cost base and improving operational efficiency. The company is currently in advanced discussions with its creditors regarding the implementation of a Company Voluntary Arrangement (CVA).

“The successful approval and implementation of the CVA is a key component of the company’s financial restructuring. The directors have prepared cash flow forecasts and projections, which incorporate the anticipated impact of the restructuring activities and the proposed CVA.

“These forecasts indicate that, subject to the successful outcome of the CVA, the company will have sufficient resources to continue trading and meet its liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements.

“However, the requirement to successfully agree and implement the CVA, represents a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. If the CVA is not approved or the anticipated support is not maintained, the company may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Advertisement
Continue Reading

Business

Monday Stock Falls As Software Maker’s Guidance Trumps Earnings Beat

Published

on

Monday.com

Monday.com (MNDY) on Monday reported second-quarter earnings and revenue that topped estimates. Monday stock fell sharply as the software maker’s revenue guidance missed targets. Monday.com reported earnings before the market open. For the quarter ending June 30, the maker of project management software reported a profit of $1.48 a share on an adjusted basis, up 36% from a year earlier.…

Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Business

Low Dollar Hedge Ratios: Could Lightning Strike Twice?

Published

on

Low Dollar Hedge Ratios: Could Lightning Strike Twice?

Low Dollar Hedge Ratios: Could Lightning Strike Twice?

Continue Reading

Business

Live webinar to analyze the state of product innovation

Published

on

Live webinar to analyze the state of product innovation

The Trends and Innovations webinar will be held on Aug. 26. 

Continue Reading

Business

CECO Environmental Corp. 2026 Q2 – Results – Earnings Call Presentation (NASDAQ:CECO) 2026-08-10

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

DigitalBridge: Strong Earnings, But The Upside Is Capped (NYSE:DBRG)

Published

on

DigitalBridge: Strong Earnings, But The Upside Is Capped (NYSE:DBRG)

This article was written by

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to working as a biotech equity analyst alongside my lab work. My focus is on identifying promising biotechnology companies that are innovating in unique and differentiated ways, whether through novel mechanisms of action, first-in-class therapies, or platform technologies with the potential to reshape treatment paradigms. By combining my lab-based scientific expertise with financial and market analysis, I aim to deliver research that is both technically sound and investment-driven. On Seeking Alpha, I plan to write primarily about the biotech sector, covering companies at different stages of development, from early clinical pipelines to commercial-stage biotechs. My approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and the potential market opportunity, all while balancing financial fundamentals and valuation. My goal in publishing here is to share some insights that help investors better understand both the opportunities and of course the many risks in biotech. This is a sector where breakthrough science can translate into outsized returns, but also where careful scrutiny is essential. I look forward to contributing thoughtful analysis and engaging with readers who share an interest in this dynamic and rapidly evolving space.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Nayax Ltd. 2026 Q2 – Results – Earnings Call Presentation (NASDAQ:NYAX) 2026-08-10

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Trending

Copyright © 2025